NeuroSense Therapeutics has gained orphan drug designation for the Ciprofloxacin Celecoxib combination pharmaceutical, PrimeC, by the European Medicine Association (EMA). The classification compliments the prior orphan drug designation by the FDA in 2020. Additionally, NeuroSense was awarded a seal of excellence by the European Commission, illustrating the potential success of this drug.
